Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)FDA agreed that a single pivotal Phase 3 trial plus confirmatory evid ...

Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)FDA agreed that a single pivotal Phase 3 trial plus confirmatory evid ...

The phase-locked loop (PLL) plays a vital role in many electronic systems and circuits. It has been used in various forms ...

Both companies are unprofitable and burning cash, but their balance sheets and risk profiles tell very different stories for ...

One company has turned cash-flow positive while burning through $661 million in capital; the other faces liquidity crises and ...

The construction of two new natural flood defences could be placed along tributaries of the River Irwell in Rossendale thanks to an investment ...

Durham-based Humacyte, a regenerative medicine company, will soon begin a first-in-human clinical study of its bioengineered blood vessel in patients undergoing coronary artery bypass grafting (CABG).

The best AI stocks that can benefit from Mag 7 earnings and capex spending are semiconductor companies with strong ...

Ambrosia Citrus Estate, near Hoedspruit in Limpopo, was established in 1999. In 2011, the estate’s journey with low-flow drip irrigation began when it became one of the first farms in South Africa to ...

Meta (META) stays a Strong Buy as AI boosts ads and engagement. Valuation is compelling at TTM P/OCF of 10. Read here for a ...

The UK's North Sea Transition Authority announced that the carbon storage industry 'has been given a significant boost' with ...

Alphabet's AI spending spree could hand Lumentum and Celestica another tailwind as demand outpaces infrastructure supply.